Skip to main content

Rhenium-186 HEDP use while Breastfeeding

Medically reviewed by Last updated on Oct 24, 2022.

Rhenium-186 HEDP Levels and Effects while Breastfeeding

Summary of Use during Lactation

Information in this record refers to the use of rhenium-186 HEDP (rhenium-186 etidronate) as a therapeutic agent. No information is available on the therapeutic use of rhenium HEDP during breastfeeding. Because strontium can substitute for calcium in infant bones, the manufacturer and expert opinion recommend discontinuing breastfeeding before a nursing mother receives rhenium HEDP.[1]

Drug Levels

Rhenium 186 emits a beta particle with a mean energy of 0.349 MeV and gamma emission with a 0.137 MeV photo peak. Its physical half-life is 3.7 days.[1]

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.


Bodei L, Lam M, Chiesa C et al. EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging. 2008;35:1934-40. [PubMed: 18649080]

Substance Identification

Substance Name

Rhenium-186 HEDP

CAS Registry Number


Drug Class

  • Breast Feeding
  • Lactation
  • Radiopharmaceuticals
  • Etidronic Acid

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.